Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Acq. announced
Consulting agrmnt
Inv. presentation
PROLOR Biotech, Inc. (PBTH) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/30/2013 8-K Quarterly results
06/07/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/04/2013 8-K Other Events, Financial Statements and Exhibits
Docs: "PROLOR BIOTECH initiates PIVOTAL phase III trial of ITS Longer-Acting Version of human growth hormone Nes-Ziona, Israel– June 4, 2013 – PROLOR Biotech, Inc. , a company developing next-generation biobetter therapeutic proteins, today announced the initiation of a pivotal Phase III clinical trial of hGH-CTP, the company’ s proprietary version of human growth hormone , in growth hormone deficient adults. PROLOR is developing hGH-CTP to provide growth hormone deficient adults and children with hGH therapy that may require only once-weekly or bi-monthly injections, rather than the daily injections required by current hGH therapy. The initiation of the Phase III clinical trial follows a set of successful Phase II trials showing that hGH-CTP has the potential to be effective when injected once w..."
06/07/2012 8-K Form 8-K - Current report
05/14/2012 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement between the Company and Jefferies, for itself and as representative of the other underwriters named therein",
"Opinion of Greenberg Traurig, LLP",
"PROLOR BIOTECH Announces PROPOSED Public Offering of Common Stock Nes-Ziona, Israel – May 10, 2012 – PROLOR Biotech, Inc. today announced that it intends, subject to market conditions, to offer and sell shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as the sole book-running manager and Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. and Oppenheimer & Co. Inc. are acting as co-managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. PROLOR intends to use the net proceeds from this offering for general corporate purposes, which may include research and...",
"PROLOR BIOTECH Announces PRICING OF Public Offering of Common Stock Nes-Ziona, Israel – May 11, 2012 – PROLOR Biotech, Inc. , today announced the pricing of its previously announced underwritten public offering of 6.5 million shares of its common stock at a price to the public of $5.00 per share. The gross proceeds to PROLOR from this offering are expected to be $32.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by PROLOR. PROLOR has granted the underwriters a 30-day option to purchase up to an aggregate of 975,000 shares of common stock to cover over-allotments, if any. The offering is expected to close on May 16, 2012, subject to customary closing conditions. Jefferies & Company, Inc. is acting as the sole book-running man..."
04/20/2012 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure...
Docs: "PROLOR Biotech Receives Letter from NYSE Amex Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders Nes-Ziona, Israel – April 20, 2012 – PROLOR Biotech, Inc. today announced that it received a letter from NYSE Regulation regarding a late notification to NYSE Amex of the “record date” for this year's Annual Stockholders’ Meeting. April 12, 2012 was set as the record date for PROLOR’ s Annual Meeting, meaning stockholders as of April 12, 2012 are entitled to vote their respective shares at PROLOR's 2012 Annual Meeting, which is scheduled for June 5, 2012. A company listed on the NYSE Amex is required to provide the Exchange with notice of the record date for its Annual Stockholders’ meeting at least 10 days prior to the record date. PROLOR provided late notice of the..."
04/19/2012 8-K Investor presentation
Docs: "Slide Presentation"
02/24/2012 8-K Form 8-K - Current report
06/09/2011 8-K Form 8-K - Current report
04/14/2011 8-K Form 8-K - Current report
02/16/2011 8-K Form 8-K - Current report
01/06/2011 8-K Form 8-K - Current report
07/21/2010 8-K Form 8-K - Current report
06/09/2010 8-K Submission of Matters to a Vote of Security Holders
05/26/2010 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "PROLOR BIOTECH ANNOUNCES NEW LISTING ON TEL AVIV STOCK EXCHANGE"
05/05/2010 8-K Regulation FD Disclosure
05/03/2010 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "PROLOR BIOTECH REPORTS NEW PRECLINICAL DATA SUPPORTING THE ENHANCED BIOLOGICAL ACTIVITY POTENTIAL OF ITS BIOBETTER PIPELINE Nes-Ziona, Israel– May 3, 2010 – PROLOR Biotech, Inc. , a company developing next generation biobetter therapeutic proteins, today reported new preclinical data on the company’s pipeline of drug candidates designed to reduce the dosing frequency of therapeutic proteins and peptides. The data will be discussed by PROLOR’s management at the 2010 BIO International Convention in Chicago, as well as at the upcoming Rodman & Renshaw 6th Annual Global Healthcare Conference in London and the Jefferies 2010 Global Life Sciences Conference in New York City. The data includes an update on PROLOR’s preclinical development program for its CTP-enhanced version of interferon beta , ..."
04/12/2010 8-K Form 8-K - Current report
04/01/2010 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "PROLOR BIOTECH AWARDED SECOND ISRAELI GOVERNMENT GRANT TO SUPPORT DEVELOPMENT OF ITS LONGER-ACTING INTERFERON BETA -- Interferon-Beta-CTP Development Program Has Been Approved For Second Year Funding Through a Special Grant from the Israeli Office of the Chief Scientist -- Nes-Ziona, Israel – April 1, 2010 – PROLOR Biotech, Inc. , a company developing next generation biobetter therapeutic proteins, today announced that the Israeli Office of the Chief Scientist has approved a 2010 continuation of its grant to PROLOR’s Israeli-based R&D subsidiary for the company’s development program for interferon-beta-1a-CTP , its longer-acting version of interferon-beta-1a . IFN-Beta, which is indicated for the treatment of multiple sclerosis , is currently marketed by Merck Serono as Rebif® and by Bioge..."
03/25/2010 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "PROLOR BIOTECH ANNOUNCES NYSE AMEX LISTING"
03/18/2010 8-K Form 8-K - Current report
03/17/2010 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Form of Securities Purchase Agreement",
"Form of Lockup Agreement"
01/25/2010 8-K Form 8-K - Current report
07/27/2009 8-K Form 8-K - Current report
07/24/2009 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Secu...
Docs: "Certificate of Designation of Series B Preferred Stock",
"Specimen Certificate for Series B Preferred Stock",
"Securities Purchase Agreement",
"Form of Lockup Agreement",
"Letter Agreement",
"PROLOR BIOTECH ANNOUNCES $10 MILLION PREFERRED STOCK LINE FROM MEMBERS OF THE FROST GROUP"
06/12/2009 8-K Other Events, Financial Statements and Exhibits
Docs: "MODIGENE SHAREHOLDERS APPROVE COMPANY NAME CHANGE AND OTHER PROPOSALS AT ANNUAL MEETING"
05/28/2009 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Second Amendment to the Modigene Inc. 2007 Equity Incentive Plan (filed herewith)"
04/27/2009 8-K Form 8-K -- Current report
02/10/2009 8-K Form 8-K -- Current report
09/22/2008 8-K Form 8-K -- Current report
09/12/2008 8-K Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Financial State...
Docs: "Letter dated September 11, 2008, from Yarel + Partners to the Securities and Exchange Commission"
07/18/2008 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ...
Docs: "Amendment to Consulting Agreement between the Company and Avri Havron",
"Amendment to Employment Agreement between the Company and Shai Novik",
"Amendment to Consulting Agreement between the ModigeneTech Ltd. and Fuad Fares",
"Amendment to Employment Agreement between the ModigeneTech Ltd. and Eyal Fima"
03/27/2008 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
03/06/2008 8-K Termination of a Material Definitive Agreement, Departure of Directors or Principal Officers; Election of Directors; Appointm...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy